AIM ImmunoTech Inc. (AIM) Completes Final Ampligen Dosing in DURIPANC; Topline Data Expected 1Q27

AIM ImmunoTech completed final dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with topline data expected in Q1 2027. The company also reported encouraging findings from a Netherlands Named Patient Program.

Original reporting
Published Oct 1, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AIM ImmunoTech Inc. (AIM) Completes Final Ampligen Dosing in DURIPANC; Topline Data Expected 1Q27 — source image
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

Completion of dosing signals progress toward a pivotal readout, which historically moves small‑cap biotech stocks sharply on results.

02

Market read

The announcement is a typical catalyst for biotech equities, likely to generate short‑term price volatility ahead of the Q1 2027 data release.

03

What to watch

Potential competition from other immunotherapy candidates and the need for further Phase 3 funding.

Relevance 7/10Novelty 7/10Timing: pre‑Q1 2027 readout

Background

AIM ImmunoTech is a clinical‑stage biotech focused on immunomodulatory therapies. The DURIPANC trial evaluates Ampligen in metastatic pancreatic cancer.

Company-level read

Ticker impact

$AIMNeutralHigh confidence
Context

AIM ImmunoTech announced completion of final Ampligen dosing in its Phase 2 DURIPANC pancreatic cancer trial, with topline results expected in Q1 2027.

Expected impact

potential upside as market prices in the upcoming topline readout

Evidence & confidence

Trial progress is material for a biotech; investors typically bid up shares ahead of data releases.

Market effects

Adds to momentum in the oncology biotech space as investors watch early‑stage trial milestones.

Limited to US biotech investors; no broader regional effect.

Minor global relevance; primarily of interest to specialty‑medicine traders.

Counterpoint

If the trial data ultimately miss expectations, the stock could face a sharp correction despite the dosing milestone.

Key entities

  • AIM ImmunoTech Inc.

    US‑listed biotech developing Ampligen.

Related articles

$AIMLow

AIM ImmunoTech completes dosing in pancreatic cancer trial

AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.